Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: Protection against Bordetella pertussis challenge in neonates

Full text
Author(s):
Nascimento, Ivan P. [1] ; Dias, Waldely O. [1] ; Quintilio, Wagner [2] ; Hsu, Tsungda [3] ; Jacobs, Jr., William R. [4, 3] ; Leite, Luciana C. C. [1]
Total Authors: 6
Affiliation:
[1] Inst Butantan, Ctr Biotecnol, BR-05503900 Sao Paulo - Brazil
[2] Inst Butantan, Div Controle Qualidade, BR-05503900 Sao Paulo - Brazil
[3] Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 - USA
[4] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 - USA
Total Affiliations: 4
Document type: Journal article
Source: Vaccine; v. 27, n. 52, p. 7346-7351, DEC 9 2009.
Web of Science Citations: 17
Abstract

Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Delta lysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-Delta lysA-S1PT-lysA(+)(kan(-)), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice. (C) 2009 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 96/11539-0 - Development of a recombinant BCG vaccine - DPT
Grantee:Luciana Cezar de Cerqueira Leite
Support type: Regular Research Grants